Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents

Journal of Chemotherapy

Volumn 21, Issue 5, 2009, Pages 542-549

  Smith, V ^a   Dai, F ^a   Spitz, M ^a   Peters, G J ^b   Fiebig, H H ^a   Hussain, A ^c   Burger, A M ^d  

^a CHARLES RIVER LABORATORIES   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anticancer drugs; Drug resistance; Glutathione; MRP1; P glycoprotein; PARP cleavage; Telomerase activity; Telomere length

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GLUTATHIONE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; TELOMERASE; VINDESINE; ANTINEOPLASTIC AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CELL LINEAGE; CELL STRESS; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; LUNG CANCER; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RESTRICTION FRAGMENT; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR CELL; CLONOGENIC ASSAY; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED;

EID: 75549090887     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.5.542     Document Type: Article

References (32)

1. Deininger M, Buchdunger E, Bruker BJ. The development of imatinib as a therapeutic agent for chronic myeloid meukemia. Blood 2005;105:2640-2652.
2. Smith V, Raynaud F, Workman P, Kelland LR. Characterization of a human colorectal carcinoma cel line with acquired resistance to flavopiridol. Mol Pharmacol 2001; 60: 885-893.
3. Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR. Establishment and characerization of acquired resistance to the farnesyl transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 2002; 8: 2002-2009.
4. Nakanishi T. Drug transporters as targets for cancer chemotheraphy. Cancer Genom Proteom 2007; 4(3):241-254.
5. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance associated proteins, J Natl Cancer Inst 2000; 92: 1295-1302.
6. Chumsri S, Phatak P, Edelman MJ, Khakpour N, Hamburger AW, Burger AM. Cancer Stem Cells and Individualized Theraphy. Cancer Genom Proteom 2007; 4: 165-174.
7. Chumsri S, Burger AM. Cancer stem cell targeted agents: Therapeutic approaches and consequences. Curr Opin Mol Ther 2008;10: 323-333.
8. Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K. Bolund L et al. Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 1988; 263: 3912-3916.
9. Tamura H, Kohchi C, Yamada R, Ikeda T, Koiwai O, Patterson E et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 1991; 19: 69-75.
10. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 1994; 47: 689-697.
11. Harris LC, Margison GP. Expression in mammalian cells of the Escherichia coli O6 alkylguanine-DNA-alkyltransferase gene ogt reduces the toxicity of alkylnitrosoureas. Br J Cancer 1993; 67: 1196-1202.
12. Eliopoulos AG, Kerr DJ, Herod J, Hodkins L, Krajewski S, Reeed JC et al. The contorl of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995; 11: 1217-1228.
13. Vilenchik M, Raffo AJ, Benimetskaya L, Shames D, Stein CA. Antisens RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agens, Cancer Res 2002; 62: 2175-2183.
14. Ishikawa T, Wright CD, Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichlorplatinum (II)-resistant huma leukemia HL-60 clels and down-regulated by cell differentiation. J. Biol Chem 1994; 269: 29085-29093.
15. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
16. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007; 152:1003-1011.
17. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A 1998; 95: 4219-4223.
18. Burger AM, Harnden P. Telomerase in germ cell tumours: inhibition of telomerase activity after cisplatin-based therapy. In: Jones I, Appelyard I. Harnden P, Joffe JK eds. Germ Cell Tumours IV, London, John Libbey & Co. Ltd. 1998: 73-80.
19. Deschatrette J, Ng KH, Gouthière L, Maigné J, Guerroui S, Wolfrom C. Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells. Anticancer Drugs 2004; 15(7): 671-678.
20. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003; 63(3):579-585.
21. Blackburn EH, Telomere states and cell fates. Nature 2000; 408: 53-56.
22. Roth T, Burger AM, Dengler W, Fiebig HH.: Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug development. In: Fiebig HH, Burger AM, eds. Relevance of tumor models for anticancer drug development, Contributions to Oncology, vol. 54, Basel: Karger Verlag, 1999; 145-156.
23. Ruiz van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann APA, Hermsen M et al. Development and characterization of a 2', 2'- difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Res 1994; 54: 4138-4143.
24. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 1996; 2: 521-530.
25. Bergman AM, Giaccone G, Van Moorsel CJA, Mauritz R, Noordhuis P, Pinedo HM et al. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine) resistant human ovarian cancer cell line AG600 to standard and investigational drugs. Eur J Cancer 2000; 36: 1974-1983.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
27. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established humor tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004; 40: 802-820.
28. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationship between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-220.
29. Cookson JC, Dai F, Smith V, Heald RA, Laughton CA, Stevens MFG et al. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 2005; 68: 15551-15558.
30. Peters GJ, Van Moorsel CJA, Lakerveld B, Smid K, Noordhuis P, Comijn EC, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin sensitive or resistant human ovarian cancer cell lines. Int J Oncol 2006; 28: 237-244.
31. Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H et al. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy 2001; 47: 136-142.
32. Phatak P, Dai F, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H et al. KML001 (sodium meta arsenite) cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin. Cancer Res 2008: 14: 4593-4602.